Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU, US & Japan Tackle Difficulties With Randomized Trials Involving Multi-Drug Resistant Bacteria

Executive Summary

The European Medicines Agency has given the Pink Sheet more detail on its recent agreement with its counterparts in the US and Japan to align certain clinical data requirement to stimulate the development of new treatments to fight antimicrobial resistance.


Related Content

Faster AMR Drug Reviews And A New Pathogen List On Health Canada’s Agenda
Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts